Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
103.20    -5.80 (-5.32%)
Bid:
103.00
Ask:
104.20
Spread: 1.20 (1.165%)
Market Cap: £169.19m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Trading Update

2 Jul 2015 07:00

RNS Number : 9208R
Synthomer PLC
02 July 2015
 

2nd July 2015

Synthomer plc

Trading Update

Synthomer plc ('Synthomer' or 'the Group') today issues a Trading Update ahead of its Interim Results on Tuesday 11 August 2015.

Overall, the Board's expectations for the full year remain unchanged.

Europe and North America

In our Q1 trading update, we reported that volumes were slightly behind the same period in 2014. We continued to see a similar trend in Q2, with volumes lower than the prior period primarily due to weaker demand in our Paper and Carpets businesses. As expected, the small margin benefit we experienced in Q1 from declining raw material prices did not continue in Q2, as modest raw material price inflation returned. Overall, operating profit in our Europe and North America segment is marginally behind the prior period in local currency, further behind on a reported basis (H1 2014: £47.8m) due to the weak Euro and consequently slightly behind current market expectations.

Asia and Rest of World

Our Asia and Rest of World segment has continued to experience both improved unit margins and strong demand similar to that seen in the first quarter, particularly in our Asian nitrile business. We have seen good volume growth and substantial margin growth, relative to the weaker performance in the first half of 2014. As a result, operating profit in our Asia and Rest of World segment for the first half of 2015 is materially ahead of the prior period (H1 2014: £7.3m) and current market expectations.

Financial Position

The Group continues to generate strong cash flows from all its operations and this, together with the benefit of the translation of the Euro denominated debt, will result in a further significant reduction in net debt at the end of the first six months. 

The Final 2014 Ordinary Dividend of 4.8p per share and the Special Dividend of 7.8p per share will be paid on 3 July 2015 resulting in a total cash payment to shareholders of approximately £43m.

Outlook

Looking forward to the second half, the economic and currency challenges in Europe are expected to have a continued impact on performance. This will be offset by Asia and Rest of World where, despite some softening in market conditions at the end of the first half, we remain confident of a continued strong performance. Overall, the Board's expectations for the full year remain unchanged.

 

Enquiries:

 

Calum MacLean, Chief Executive Officer

Tel: 01279 436 211

Stephen Bennett, Chief Financial Officer

Tel: 01279 775 250

Charles Armitstead, Pendomer

Tel: 020 3603 5220

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTGMGGNVMVGKZM
Date   Source Headline
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration
13th Feb 20257:00 amRNSHolding(s) in Company
28th Jan 202510:30 amRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSWinter trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.